|
⚲
|
| Keyboard |
| Matrix Capital Group Inc
✚
|
|
|---|---|
| CRD # | 33364 |
| SEC # | 801-61224 |
| CIK # | 0001906866, 0001410830 |
| AUM | |
| Employees | 4 (50% Investors, 50% Brokers) |
| Fees | |
| Minimum | |
| Phone | 816-787-0718 |
| Address | 106 West 32nd Street New York, NY 10001 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($M) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/30/2016) [Brochure] |
|---|
ITEM 5 -- FEES AND COMPENSATION
Fees for Investment Advisory Services are based upon a percentage of Assets Under Management
(“AUM”) and generally range from 0.20% to 0.50%, annually. Fees are based on the account’s asset
value as of the last business day of the prior calendar period, depending upon whether fees are paid
monthly or quarterly. Fees are billed monthly or quarterly in arrears as stated in the client’s agreement.
Fees are on a negotiated basis and depend on the degree of complexity associated with the client’s
situation. Fees are provided in a schedule of disclosed fees in each client agreement.
Matrix Capital Group, Inc. Page 3
Additional Fees and Expenses. Matrix fees are exclusive of any additional charges, commissions or
fees imposed by custodians, brokers, third party investment managers and other third parties such as
investment manager fees, custodial fees, deferred sales charges, wire transfer and electronic fund fees,
and other fees and taxes on brokerage accounts and securities transactions. Mutual Funds and
exchange traded funds also charge internal management fees, which are disclosed in a fund’s
prospectus, all of which are exclusive of and in addition to Matrix Capital Group’s fee.
Fees Offset By Commission and Other Fees. Management personnel and other related persons of
our firm are licensed as registered representatives of Matrix Capital Group, Inc., a broker-dealer (Please
refer to Item 10, “Other Financial Industry Activities and Affiliations,” for a detailed explanation of these
relationships and important conflict of interest disclosures). This presents a potential conflict of
interest, which gives such personnel and other related persons of the firm an incentive to recommend
investment products based on the compensation received, rather than on a client’s needs.
In their separate capacity(ies), these individuals may earn separate and typical compensation, i.e.,
commissions, 12b-1 fees, “trailing fees” (compensation for allocating client assets to hedge funds) or
other sales-related forms of compensation, for transactions in advisory accounts. As a matter of firm
policy, Matrix takes the following steps with regard to any potential investment as to which either
Matrix or its employees may receive compensation in the form of commissions, trailing fees, etc., in
their capacity as licensed representatives of Matrix Capital Group, Inc. (a FINRA broker-dealer):
1. Matrix discloses the potential for the firm or its employees to earn such additional
compensation in advance of the investment being made;
2. If the client then chooses to make the recommended investment, Matrix excludes all such assets
from the Assets Under Management as to which Advisory Fees may be paid; and,
3. Matrix continuously highlights the existence of the excluded assets by showing them as non-
billed assets on each subsequent billing statement.
In addition to these procedures, Clients always have the option to purchase investment products Matrix
recommends through other brokers or agents that are not affiliated with Matrix.
All applicable and potentially applicable conflicts of interest of which Matrix is aware are fully disclosed
to our clients. For detailed information about how Matrix addresses conflicts that arise, including
procedures used for disclosing conflicts to clients, please refer to Item 10, “Other Financial Industry
Activities and Affiliations.”
Fee Billing. The specific manner in which fees are charged by Matrix is established in a client’s
agreement. Client’s may elect to be billed directly for fees or to authorize Matrix to directly debit the
Client’s account for the amount of the total advisory fee and directly remit that management fee to
Matrix in accordance with applicable custody rules.
Prepayment of Fees. Under no circumstances does Matrix require prepayment of fees.
Matrix Capital Group, Inc. Page 4 |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/30/2016) [Brochure] |
|---|
ITEM 7 -- TYPES OF CLIENTS Our ideal clients include foundations and high net worth families and individuals and other institutional clients. |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| AURA Biosciences Inc | 0.0 | ||
| Holdings by Sector ($B) |
|---|
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 0 | 0.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 1 | 30.0 |
| By Discretionary | ||
| Discretionary | 0 | 0.0 |
| Non-Discretionary | 1 | 30.0 |
| Total | 1 | 30.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 30.0 | |
| Total | 1 | 30.0 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001410830] | |
| 3 | [0001410830] | |
| 4 | [0001410830] | |
| SC 13D | [0001410830] | |
| SC 13G | [0001410830] | |
| 13F-HR | [0001906866] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Matrix Capital Management Company LP | |
| Aura Biosciences Inc | |
| GOEL David E | |
| Zentalis Pharmaceuticals Inc | |
| Adaptive Biotechnologies Corp |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals Inc ZNTL
Common Stock, par value $0.001 per share
|
2025-12-15 | Sell | 7,500,000 | $1.33 | 9,975,000 |
|
Aura Biosciences Inc AURA
Common Stock, par value $0.00001 per share (Common Stock)
|
2023-11-09 | Buy | 1,560,000 | $9.00 | 14,040,000 |
|
Zentalis Pharmaceuticals Inc ZNTL
Common Stock, par value $0.001 per share
|
2023-06-20 | Buy | 4,760,000 | $22.66 | 107,861,600 |
|
Aura Biosciences Inc AURA
"Common Stock, par value $0.00001 per share (""Common Stock"")"
|
2022-12-05 | Buy | 1,250,000 | $12.00 | 15,000,000 |
|
Aura Biosciences Inc AURA
Common Stock
|
2021-11-02 | Buy | 1,785,000 | $14.00 | 24,990,000 |
|
Aura Biosciences Inc AURA
Series E Convertible Preferred Stock · derivative
|
2021-11-02 | Conversion | 2,327,870 | $0.00 | |
|
Aura Biosciences Inc AURA
"Common Stock, par value $0.00001 per share (""Common Stock"")"
|
2021-11-02 | Conversion | 2,327,870 | ||
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-10 | Sell | 30,268 | $42.38 | 1,282,758 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-10 | Sell | 25,732 | $41.47 | 1,067,106 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-09 | Sell | 34,302 | $41.16 | 1,411,870 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-09 | Sell | 215,698 | $40.42 | 8,718,513 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-08 | Sell | 71,194 | $41.21 | 2,933,905 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-08 | Sell | 234,295 | $38.22 | 8,954,755 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-08 | Sell | 75,000 | $39.22 | 2,941,500 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-08 | Sell | 33,600 | $39.97 | 1,342,992 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-08 | Sell | 85,911 | $41.62 | 3,575,616 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2020-07-20 | Sell | 2,000,000 | $40.00 | 80,000,000 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2020-01-24 | Conversion | 2,217,101 | $26.50 | 58,753,176 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2019-07-01 | Conversion | 84,359 | ||
|
Adaptive Biotechnologies Corp ADPT
Series E-1 Convertible Preferred Stock · derivative
|
2019-07-01 | Conversion | 5,893,716 | $0.00 | |
| showing 20 of 26 most recent transactions | |||||